Tests:Thrombin Clotting Time, Plasma: Difference between revisions
- Department
- Haematology
Tests:Thrombin Clotting Time, Plasma
No edit summary |
No edit summary |
||
| Line 21: | Line 21: | ||
Thrombin Time | Thrombin Time | ||
|- | |- | ||
| | |Availability | ||
|Monday - Sunday, testing routinely available out of hours | |Monday - Sunday, testing routinely available out of hours | ||
|- | |- | ||
| Line 33: | Line 33: | ||
== Specimen Requirements == | == Specimen Requirements == | ||
|- | |- | ||
|Specimen | |Specimen | ||
|Plasma | |Plasma | ||
|- | |- | ||
| Line 57: | Line 57: | ||
== Aliquot Requirements == | == Aliquot Requirements == | ||
|- | |- | ||
|Sample | |Sample | ||
| | | | ||
|- | |- | ||
Revision as of 15:18, 20 March 2025
Thrombin clotting time is performed with a coagulation screen
Overview | |
|---|---|
| Department | Haematology |
| Test Code | |
| Synonyms | TCT
Thrombin Time |
| Availability | Monday - Sunday, testing routinely available out of hours |
| Turnaround Time | 1-4 hrs |
| Stability – Add test | 24 hrs |
Specimen Requirements | |
| Specimen | Plasma |
| Preferred | Full 2.7 mL Na citrate Blue-Top |
| Acceptable | |
| Unacceptable | Clotted samples
Under or overfilled tubes Grossly haemolysed Samples older than 24 hours |
| Specimen Transportation | |
| Paediatric Requirements | 1 mL Na Citrate Blue-Top |
Aliquot Requirements | |
| Sample | |
| Preferred Volume | |
| Minimum Volume | |
| Aliquot Transportation | |
Clinical Information | |
| Reference Intervals | Reference Range: < 21 sec.
Interpretation of TCT and Protamine TCT: TCT TCT + PrSo4 Interpretation Prolonged Normal Consistent with Heparin Prolonged Prolonged Consistent with Dabigatran, DIC, low fibrinogen. |
| Test Method | Mechanical clot detection performed on Stago Compact Max2 Analyser |
| Advanced Notice | Not required |
| Patient Preparation | Not required |
Comments | |
| Protamine sulphate may be added to the TCT to exclude or indicate heparin contamination.
Any prolongation of the thrombin time may indicate the presence of a high level fibrin degradation products, hypo- or afibrinogenemia, dysfibrinogenemia, the presence of Heparin, Dabigatran, or a high concentration of serum proteins. | |